KNOW HEADACHE & MIGRAINE PAIN
Migraine Module Development Committee

Işin Ünal-Çevik, MD, PhD
Neurologist, Neuroscientist and Pain Specialist
Ankara, Turkey

Peter Goadsby, MD, PhD
Neurologist
UK/USA

Michel Lanteri-Minet, MD, PhD
Neurologist
Nice, France

Raymond L. Rosales, MD, PhD
Neurologist
Manila, Philippines

Stewart Tepper, MD, PhD
Neurologist
Cleveland, USA

This program was sponsored by Pfizer Inc.
Learning objectives

After completing this module, participants will be able to:

• Understand the pathophysiology of migraine
• Discuss the prevalence of migraine
• Recognize the signs and symptoms of migraine
• Assess the impact of migraine on patients’ quality of life and ability to work
• Apply diagnostic criteria at the appropriate time
• Understand the goals of managing migraine
• Understand the impact of migraine and comorbidities
• Select appropriate pharmacological and non-pharmacological strategies for the management of migraine
Headache Classification

- 1988: International Headache Society (IHS)
- 2003: International Classification of Headache Disorders-II (ICHD-II)
- 2013: ICHD-III-beta: Headache Classification Committee of the IHS: The International Classification of Headache Disorders, 3rd edition (beta version)

Access the current IHS classification:


Learners should consult both the classification and the accompanying notes for full information

<table>
<thead>
<tr>
<th>Part One: The Primary Headaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Migraine</td>
</tr>
<tr>
<td>2. Tension-type headache</td>
</tr>
<tr>
<td>3. Trigeminal autonomic cephalalgias</td>
</tr>
<tr>
<td>4. Other primary headache disorders</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part Two: The Secondary Headaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Headache attributed to trauma or injury to the head and/or neck</td>
</tr>
<tr>
<td>6. Headache attributed to cranial or cervical vascular disorder</td>
</tr>
<tr>
<td>7. Headache attributed to non-vascular intracranial disorder</td>
</tr>
<tr>
<td>8. Headache attributed to a substance or its withdrawal</td>
</tr>
<tr>
<td>9. Headache attributed to infection</td>
</tr>
<tr>
<td>10. Headache attributed to disorder of homeostasis</td>
</tr>
<tr>
<td>11. Headache or facial pain attributed to disorder of the cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other facial or cervical structure</td>
</tr>
<tr>
<td>12. Headache attributed to psychiatric disorder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part Three: Painful Cranial Neuropathies, Other Facial Pains and Other Headaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Painful cranial neuropathies and other facial pains</td>
</tr>
<tr>
<td>14. Other headache disorders</td>
</tr>
</tbody>
</table>

ICHD = International Classification of Headache Disorders
Headache Disorders

• Among the most common disorders of the nervous system
• Associated with
  • Personal burden of pain
    • Negative impact of pain
    • Reduced quality of life
    • Disability
  • Societal burden of pain
    • Direct costs
    • Indirect costs
• A minority of people with headache disorders are appropriately diagnosed

Headache has been underestimated, under-recognized, and under-treated throughout the world

What Is Migraine?

• Central nervous system disorder
• Common clinical syndrome
• Characterized by recurrent episodic attacks of headache with pulsating quality and moderate to severe intensity, which serve no protective purpose

• Migraine can be accompanied by the following symptoms
  • Aura
  • Nausea / Vomiting
  • Sensitivity to light (photophobia)
  • Sensitivity to sound (phonophobia)
  • Sensitivity to head movement

• Vulnerability to migraine is inherited in many people

Classification of Migraine

Migraine without aura
• Recurrent attacks
• Attacks and associated migraine symptoms last 4-72 hours

Migraine with aura (migraine with typical aura, migraine with brainstem aura, hemiplegic migraine, retinal migraine)
• Visual and/or sensory and/or speech/language symptoms and/or motor weakness
• Gradual development of aura
  • At least one symptom spreads gradually over ≥5 minutes
  • Symptoms last ≥5 and ≤60 minutes
• Can be positive or negative symptoms or a mixture
• Complete reversibility

Chronic Migraine
• In a patient with previous episodic migraine
• Headache on ≥15 days/month for >3 months
• Headache has features of migraine on ≥8 days/month
WHAT ARE THE MOST COMMON TYPES OF HEADACHES YOU SEE IN YOUR PRACTICE?
Pathophysiology of Migraine
Central Sensitization/Alloodynia in Migraine

- Sensory sensitivity is increased during a migraine attack
- Symptoms are regulated by **central or peripheral** mechanisms
  - Peripheral sensitization leads to throbbing and exacerbation of pain with movement
  - Central sensitization leads to cutaneous allostodynia
Migraine Aura

Relative timing of cerebral blood flow (CBF), aura, and headache*

CBF = cerebral blood flow
Prevalence of Migraine
Prevalence of Migraine

- Prevalence of migraine in the general population is 10 to 12%
- Prevalence of chronic migraine is 2 to 4%

*Symptomatic at least once within the last year

Heritability of Migraine: When Patients Ask “Why Me?”

- Studies have identified 13 migraine-associated variants pointing at genes that cluster in pathways for glutamatergic neurotransmission, synaptic function, pain sensing, metalloproteinases, and vasculature.

- Individual pathogenic contribution of each gene variant is difficult to assess
  - Small effect sizes and complex interactions.

- Six genes with large effect sizes identified in patients with rare monogenic migraine syndromes in which hemiplegic migraine and non-hemiplegic migraine with or without aura are part of a larger clinical spectrum.

- Transgenic mouse models with human monogenic-migraine-syndrome gene mutations showed migraine-like features and increased susceptibility to cortical spreading depression.

Hormonal Changes and Incidence of Migraine without Aura in Women

Pregnancy and Migraines

• Most female migraineurs (up to 80%) note remarkable and increasing improvement of their attacks during pregnancy
  – Fewer attacks
  – Improvement more likely in women with menstrual migraine
• If migraine does not improve by end of first trimester, it will likely continue throughout pregnancy
• In some women, migraine worsens during pregnancy
  – Involves women with migraine with aura
• Some women develop de novo migraine during pregnancy
  – Mostly migraine with aura
• Migraine attacks return after delivery in nearly all women

Migraine and Oral Contraceptives

- Must consider the risk of stroke and venous thromboembolism in migraine
  - Combination oral contraceptives (OCs) increase risk
- Risk is similar in women with migraine without and women without migraine

WHO recommends women with migraine with aura avoid combination OCs

WHO = World Health Organization
Signs and Symptoms of Migraine
Core Symptoms of Migraine

- Duration: 4 to 72 hours if untreated/unsuccessfully treated
  - Duration of 2 to 72 hours in patients <18 years of age
- Pain:
  - Throbbing or pulsatile headache
  - Moderate to severe; intensifies with movement/physical activity
  - Unilateral pain in 60%, bilateral in 40%
  - Pain can be felt anywhere around the head or neck, and location does not make the diagnosis
  - Pain be rapid onset or more indolent
- Nausea (80%) and vomiting (50%)
  - Can have anorexia, food intolerance, light-headedness, frank nausea or dislike of light and noise during the premonitory phase and during the attack itself
Chronic Migraine (CM)

• Typically develops after a slow increase in headache frequency over years to months (“migraine transformation”)
  • 2-4% of people with episodic migraine transform to CM yearly
• Population studies indicate a prevalence of 1.4% to 2.2%
• ≥50% of patients with CM have medication overuse headache
• Patients with CM often revert to episodic migraine with treatment
## Factors Associated with Transformation and Reversion of Chronic Migraine (CM)

<table>
<thead>
<tr>
<th>Transformation to CM</th>
<th>Reversion of CM</th>
</tr>
</thead>
<tbody>
<tr>
<td>• High baseline headache frequency                                                   • Adherence to migraine prophylactic drugs</td>
<td></td>
</tr>
<tr>
<td>• Overuse of migraine acute drugs                                                    • Lower baseline headache frequency</td>
<td></td>
</tr>
<tr>
<td>• Ineffective acute migraine treatment                                               • Absence of cutaneous allodynia</td>
<td></td>
</tr>
<tr>
<td>• Nausea                                                                              • Physical exercise</td>
<td></td>
</tr>
<tr>
<td>• Obesity                                                                             • Withdrawal of overused migraine abortive drugs</td>
<td></td>
</tr>
<tr>
<td>• Snoring                                                                             • Lower socioeconomic status</td>
<td></td>
</tr>
<tr>
<td>• Sleep disorders                                                                     • Absence of cutaneous allodynia</td>
<td></td>
</tr>
<tr>
<td>• Excessive caffeine intake                                                           • Physical exercise</td>
<td></td>
</tr>
<tr>
<td>• Psychiatric disease                                                                 • Withdrawal of overused migraine abortive drugs</td>
<td></td>
</tr>
<tr>
<td>• Major life changes                                                                  • Lower baseline headache frequency</td>
<td></td>
</tr>
<tr>
<td>• Head or neck injury                                                                 • Absence of cutaneous allodynia</td>
<td></td>
</tr>
<tr>
<td>• Cutaneous allodynia                                                                  • Physical exercise</td>
<td></td>
</tr>
<tr>
<td>• Female gender                                                                       • Withdrawal of overused migraine abortive drugs</td>
<td></td>
</tr>
<tr>
<td>• Comorbid pain disorders                                                              • Lower socioeconomic status</td>
<td></td>
</tr>
<tr>
<td>• Lower socioeconomic status                                                          • Absence of cutaneous allodynia</td>
<td></td>
</tr>
</tbody>
</table>

Medication Overuse Headache (MOH)

• Headache occurring on >15 days/month
• Develops as a consequence of regular overuse of acute or symptomatic headache medication (on ≥10 or ≥15 days per month, depending on the medication) for >3 months
• Usually, but not invariably, resolves after the overuse is stopped
• Around 50% of patients with chronic migraine revert to an episodic migraine subtype after drug withdrawal

Subtypes of Medication-overuse Headache (MOH)

- Intake on ≥10 days/month on a regular basis for >3 months:
  - Ergotamine-overuse headache
  - Triptan-overuse headache
  - Opioid-overuse headache
  - Combination analgesic-overuse headache
Typical Features of Migraine Aura

- May precede or accompany headache phase or may occur in isolation
- Usually develops over 5 minutes and lasts <1 hour
- Typical aura is most commonly visual, but can be sensory or speech/language, or a combination
- Visual symptoms can be positive or negative
- Most common positive visual phenomenon is the scintillating scotoma, an arc or band of absent vision with a shimmering or glittering zigzag border

Migraine Visual Aura

Lashley’s Aura
Migraine Aura

Migraines cause loss of vision in the face, which improves as the scintillating symptoms move to the side.
Somatosensory Symptoms in Migraine (Paresthesia-hypoesthesia)

Assessment and Diagnosis of Migraine
Discussion Question

HOW DO YOU ASSESS MIGRAINE IN YOUR PRACTICE?
Importance of Diagnosing Migraine

- **Improved** quality of life
- **Reduced**
  - Disability
  - Patient dependence on opioids
  - Overuse of analgesic medications or opioids
  - Risk of complications or medication overuse headaches
  - Chance of progressing to chronic daily headache (CDH)

Consequences of non-diagnosis include disabling illness, reduced quality of life, and loss of opportunities for early intervention.
Headache and Patient History: Key Questions to Ask Patients

- **Onset**: Abrupt? Gradual?
- **Frequency/duration**: 
  - How many times per week/month/year?
  - Approximate duration (two hours, 12 hours, two days etc.)
- **Location***: Uni- or bilateral? Frontal, temporal or fronto-temporo-occipital?
- **Severity of pain**: Worst-ever headache? Mild, moderate, severe?
- **Characteristics and other accompanying symptoms**
- **Medication use**: Direct relationship with a certain medication?
- **Family history of migraine**?
- **What makes the headache better or worse**?
- **Any recent change in headache pattern**?
- **Degree of disability**?
- **Comorbid conditions**?

*If episodic headache

Diagnostic Evaluation for Migraine

HEADACHE

Warning signs?

Diagnosis

Primary Headache

Atypical Features

Investigations

Secondary Headache

NO

YES

# Red Flags in Headache Diagnosis

<table>
<thead>
<tr>
<th>Red Flag</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache with systemic illness (fever, stiff neck, rash)</td>
<td>• Meningitis</td>
</tr>
<tr>
<td></td>
<td>• Encephalitis</td>
</tr>
<tr>
<td></td>
<td>• Lyme disease</td>
</tr>
<tr>
<td></td>
<td>• Systemic infection</td>
</tr>
<tr>
<td></td>
<td>• Collagen vascular disease</td>
</tr>
<tr>
<td>New onset headache in a patient with HIV or cancer</td>
<td>• Meningitis</td>
</tr>
<tr>
<td></td>
<td>• Brain abscess</td>
</tr>
<tr>
<td></td>
<td>• Metastasis</td>
</tr>
<tr>
<td>Presence of neurological deficits, papilledema or change in cognition</td>
<td>• Mass lesion</td>
</tr>
<tr>
<td></td>
<td>• Stroke</td>
</tr>
<tr>
<td></td>
<td>• Intracranial hypertension</td>
</tr>
</tbody>
</table>

Images represent conditions in boldface
# Red Flags in Headache Diagnosis

<table>
<thead>
<tr>
<th>Red Flag</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudden onset headache</td>
<td>• Subarachnoid hemorrhage&lt;br&gt;• Reversible cerebral vasoconstriction syndrome&lt;br&gt;• Cervical artery dissection&lt;br&gt;• Cerebral venous thrombosis&lt;br&gt;• Pituitary apoplexy&lt;br&gt;• Bleed into a mass or arteriovenous malformation&lt;br&gt;• Mass lesion</td>
</tr>
<tr>
<td>Headache begins in patient &gt;50 years of age</td>
<td>• Giant cell arteritis (temporal arteritis)&lt;br&gt;• Mass lesion</td>
</tr>
<tr>
<td>Accelerating pattern of headaches</td>
<td>• Mass lesion&lt;br&gt;• Subdural hematoma&lt;br&gt;• Medication overuse</td>
</tr>
</tbody>
</table>

Images represent conditions in boldface.

ICHD-3 Diagnostic Criteria for Migraine without Aura

A. At least five attacks fulfilling criteria B to D

B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)

C. Headache has ≥2 of the following characteristics
   1. Unilateral location
   2. Pulsating quality
   3. Moderate or severe pain intensity
   4. Aggravation by or causing avoidance of routine physical activity*

D. During headache ≥1 of the following
   1. Nausea and/or vomiting
   2. Photophobia and phonophobia
   3. Not better accounted for by another ICHD-3 diagnosis

*For example, walking or climbing stairs
ICHDP = International Classification of Headache Disorders
ICHD-3 Diagnostic Criteria for Migraine with Aura

A. At least two attacks fulfilling criteria B and C
B. One or more of the following fully reversible aura symptoms:
   1. Visual
   2. Sensory
   3. Speech and/or language
   4. Motor
   5. Brainstem
   6. Retinal
C. At least two of the following:
   1. At least one aura symptom spreads gradually over ≥5 minutes, and/or two or more symptoms occur in succession
   2. Each individual aura symptom lasts 5 to 60 minutes
   3. At least one aura symptom is unilateral
   4. The aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischemic attack has been excluded

**Link to ICHD-3 Diagnosis of Migraine with Aura**

ICHD = International Classification of Headache Disorders
ICHDI-3 Diagnostic Criteria for Chronic Migraine

A. Headache (tension-type-like and/or migraine-like) on ≥15 days/month for >3 months and fulfilling criteria B and C

B. Occurring in a patient who has had ≥5 attacks fulfilling criteria B to D for Migraine with aura and/or criteria B and C for Migraine with aura

C. On ≥8 days/month for >3 months, fulfilling any of the following:
   1. Criteria C and D for Migraine without aura
   2. Criteria B and C for Migraine with aura
   3. Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative

D. Not better accounted for by another ICHD-3 diagnosis

Link to ICHD-3 Diagnosis of Chronic Migraine

ICHDI = International Classification of Headache Disorders
Tools for Migraine Evaluation, Treatment, and Imaging
Headache Diary

Patients should record:
- Date, time of onset and end
- Preceding symptoms
- Intensity on scale
- Suspected triggers
- ANY medication taken, including over-the-counter medication – note dosage taken, how many pills the patient took that day
- Relief (complete/partial/none)
- Relationship to menstrual cycle

## Brief Screeners for Migraine, Migraine Impact, and Response to Treatment

<table>
<thead>
<tr>
<th>Screening and Diagnosis</th>
<th>Test</th>
<th>Comments</th>
</tr>
</thead>
</table>
|                         | ID Chronic Migraine\(^1\) | • 12-items; identifies patients with chronic migraine  
• Can be used by patients or physicians |
|                         | ID-Migraine\(^2\) | • 3-item tool  
• Simple and reliable; use in primary care |

<table>
<thead>
<tr>
<th>Assess Migraine Impact</th>
<th>Test</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIDAS (Migraine Disability Assessment)(^3)</td>
<td>• 5-item tool to score number of days of significant reduction in activity due to migraine in past 3 months</td>
</tr>
</tbody>
</table>
|                        | Headache Impact Test™-6 (HIT-6)\(^4\) | • Covers 6 categories  
• Useful in clinical practice and research |

<table>
<thead>
<tr>
<th>Assess Response to Therapy</th>
<th>Test</th>
<th>Comments</th>
</tr>
</thead>
</table>
|                            | Migraine Therapy Assessment Questionnaire (MTOQ\(^5\)) | • 5-item questionnaire suitable for use by GPs  
• Identifies suboptimal migraine treatment |
|                            | Migraine-ACT (Assessment of Current Therapy)\(^6,7\) | • 4-item questionnaire  
• Identifies patients whose acute therapy should change |

---

Imaging for Migraine

American Academy of Neurology
• Consider only in patients with migraine with atypical headache patterns or neurologic signs

U.S. Headache Consortium
• Consider in patients with non-acute headache and unexplained findings on neurologic exam
• No usually warranted in patients with a normal neurologic exam
  • Lower threshold may apply if headache has atypical features or does not meet strict definition of migraine

• Do not image patients with stable headaches that meet migraine criteria
• If MRI is available, do not perform CT, except in emergency settings
Patient Burden of Migraine
Economic Impact of Migraine – North America

*Migraine subject with a medical follow-up
CM = chronic migraine; EM = episodic migraine
**Economic Impact of Migraine - Europe**

* Migraine subject with a medical follow-up
CM = chronic migraine; EM = episodic migraine

Impact of Migraine on Patient’s Daily Lives

- Unable to do chores/household work: 76%
- Household work productivity reduced by ≥50%: 67%
- Missed family/social/leisure activity: 59%
- Work/school productivity reduced by ≥50%: 51%

Comorbidities of Migraine

• Strong association with¹
  • Anxiety
  • Depression
  • Sleep disorders
  • Chronic pain disorders (fibromyalgia, chronic low back pain, irritable bowel syndrome)
  • Epilepsy
  • Vertigo

• Migraine with aura, but not migraine without aura, is a risk factor for ischemic stroke and silent brain lesions on MRI²
  • Particularly in women with frequent attacks

• Anxiety in childhood³
• History of abuse in childhood⁴,⁵
• History of motion sickness in childhood⁶,⁷

Associated with headache development in adulthood

Management of Migraine
Discussion Question

HOW DO YOU TREAT MIGRAINE?
Management of Migraine

Pre-emptive Strategies
Used when a known headache trigger exists

Acute Strategies
To interrupt attacks

Preventative Strategies
To prevent attack recurrence

Evaluating Migraine Triggers

- Triggers should not be confused with cause of headache
- Not all triggers act equally to provoke headache
- Multiple triggers or combinations of triggers may be needed to provoke headache
- Types of triggers
  - Menstruation
  - Stress
  - Environmental
  - Hormonal
  - Dietary (e.g., caffeine, fasting/skipping meals, alcohol)
  - Behavioral (sleep)

Patients should be advised to avoid known triggers if possible and should be counselled on lifestyle and stress management
# Commonly Reported Migraine Triggers

<table>
<thead>
<tr>
<th>DIET</th>
<th>HORMONAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hunger</td>
<td>Menstruation</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Menopause</td>
</tr>
<tr>
<td>Additives</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Red wine</td>
<td></td>
</tr>
<tr>
<td>Artificial sweeteners</td>
<td></td>
</tr>
<tr>
<td>Monosodium glutamate</td>
<td></td>
</tr>
<tr>
<td>Citrus fruits</td>
<td></td>
</tr>
<tr>
<td>Foods containing tyramine (e.g., aged cheese)</td>
<td></td>
</tr>
<tr>
<td>Meats with nitrites</td>
<td></td>
</tr>
<tr>
<td>Caffeine/caffeine withdrawal</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ENVIRONMENTAL</th>
<th>STRESS AND ANXIETY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light glare/visual stimuli</td>
<td></td>
</tr>
<tr>
<td>Odors</td>
<td></td>
</tr>
<tr>
<td>Altitude</td>
<td></td>
</tr>
<tr>
<td>Weather change</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
</tr>
<tr>
<td>Motion sickness</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDICATIONS</th>
<th>CHRONOBIOLOGIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasodilators</td>
<td>Sleep (too little/too much)</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>Schedule change</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PHYSICAL EXERTION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
</tbody>
</table>

---

Goals of Acute Treatment for Migraine

- Treat attacks quickly and consistently and avoid recurrence
- Restore patient function in personal, social, and work domains
- Minimize the use of backup and rescue medications
- Eliminate or minimize adverse events
- Optimize self-care and reduce the need for resource use
- Provide cost-effective care
What Is Successful Treatment of a Migraine Attack?

2 hour pain-free response and sustained pain-free response (i.e., freedom from pain with no recurrence or use of rescue or study medication 2-24 hours post-dose)

|Migraine Therapy Assessment Questionnaire (MTAQ®)|
|---|---|
|**Item**|**Yes**|**No**|
|Most times, I get relief from my migraine symptoms within 2 hours after I take my migraine medicine.|☐|☐|
|Most times, I can get back to what I was doing within 2 hours after I take my migraine medication.|☐|☐|
|Most months, I get 3 or more migraines.|☐|☐|
|I take daily medicine to reduce how often I get migraines.|☐|☐|
|I know what may bring on my migraines.|☐|☐|
|Most times, I try not to use my migraine medicines right away.|☐|☐|
|In the past month, I missed some school, work, or other activity because of a migraine.|☐|☐|
|In the past 6 months, I had to go to an emergency or urgent care centre for a migraine.|☐|☐|
|I am satisfied with my migraine treatment.|☐|☐|

# U.S. Headache Consortium – Goals for Migraine Treatment

## Goals of Long-term Migraine Treatment

- Reduce migraine frequency and severity
- Reduce disability
- Improve quality of life
- Prevent headache
- Avoid escalation of medication overuse
- Educate and enable patients to manage their disease

## Goals for Successful Treatment of Acute Migraine Attacks

- Treat attacks rapidly and consistently without recurrence
- Restore patient’s ability to function
- Minimize use of back-up/rescue medications
- Optimize self-care for overall management
- Be cost-effective in overall management
- Cause minimal or no adverse effects

Overview of Migraine Treatment

Migraine treatment

Acute episodes

Prophylaxis

Non specific treatments

Specific treatments

Behavioral

Neuromodulation devices

Beta-blockers

Clacium channel blockers

Tricyclic antidepressants

Anticonvulsants

Onabotulinumtoxin A

NSAIDS

Antiemetics

Triptans

Dihydroergotamine
Non-pharmacological Management of Migraine
Procedural
Behavioral
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Massage</td>
<td>• Varying degrees of efficacy</td>
</tr>
<tr>
<td>Yoga</td>
<td>• Reduces migraine frequency and associated clinical features</td>
</tr>
</tbody>
</table>
| Relaxation, biofeedback, and behavioral therapy | • Reduce migraine frequency and severity  
• Reduce the risk of episodic into chronic migraine  
• transformation, |
| Acupuncture/Procedural          | • Conflicting data  
• One study showed acupuncture was more effective than topiramate in chronic migraine prophylaxis |
Pharmacologic Management of Migraine Attack
Stratified Care for Migraine

Considerations when Selecting a Medication for Acute Treatment of Migraine

- Frequency of headaches
- Severity of headaches
- How quickly the headache builds
- Duration of the headache
- Tendency for headache recurrences
- Disability caused by headaches
- Associated symptoms (e.g., nausea)
- Previous response to therapy
- Adverse events associated with medications
- Patient preference

- **Patients should be offered an appropriate backup medication if their initial acute medication does not provide relief**
- **Patients should have a rescue medication for use at home in case of complete treatment failure**
**Medications for the Acute Management of Migraine**

### Level A Evidence
- **Analgesic**
  - Acetaminophen

- **Ergot**
  - Dihydroergotamine (DHE)

- **NSAIDs**
  - Acetylsalicylic acid (ASA)
  - Diclofenac

- **Opioids**
  - Butorphanol (nasal)
    - Strong recommendation to **avoid** the use of butorphanol

- **Triptans**
  - Almotriptan
  - Eletriptan
  - Frovatriptan

- **Combinations**
  - Acetaminophen/ASA/caffeine
  - Sumatriptan/naproxen

### Level B Evidence
- **Antiemetics**
  - Chlorpromazine
  - Droperidol
  - Metoclopramide
  - Prochlorperazine

- **Ergots**
  - Dihydroergotamine (DHE)
  - Ergotamine/caffeine
    - Ergotamine is **not** recommended for routine use

- **NSAIDs**
  - Flurbiprofen
  - Ketoprofen
  - Ketorolac

- **Others**
  - Magnesium sulphate (MgSO₄) IV
  - Isometheptene

- **Combinations**
  - Codeine or tramadol + acetaminophen
    - Strong recommendation to **avoid** the use of butorphanol
    - Codeine- and tramadol combinations are **not** recommended for routine use

### Level C Evidence
- **Antiepileptic**
  - Valproate IV

- **Ergot**: Ergotamine
  - **Not** recommended for routine use

- **NSAID**: Phenazone

- **Opioids**
  - Butorphanol IM
  - Codeine
  - Meperidine IM
  - Methadone IM

- **Steroid**: Dexamethasone IV

- **Others**
  - Lidocaine intranasal
  - Butalbital
    - Strong recommendations to **avoid** use of butalbital-containing medications

- **Combinations**
  - Butalbital/acetaminophen/caffeine/codeine
  - Butalbital/acetaminophen/codeine
    - Strong recommendations to **avoid** use of butorphanol and opioid medications

---

NSAID = non-steroidal anti-inflammatory drug; IM = intramuscular; IV = intravenous
Acute Management of Migraine during Pregnancy

- Non-pharmacological approaches (relaxation, biofeedback, physical therapy) are safe and may be effective
- Acetaminophen (paracetamol) is the drug of choice for mild to moderate pain throughout pregnancy
- Acetylsalicylic acid (Aspirin®) are safe in the first and second trimesters but should be avoided near term
- If no other treatment is effective, sumatriptan is the triptan of choice
- Antiemetics (domperidone, metoclopramide) can be used

Ergotamine and dihydroergotamine are contraindicated during pregnancy
Migraine Prophylaxis during Pregnancy

- Non-pharmacological approaches (relaxation, biofeedback, physical therapy) are safe and may be effective
- Use migraine prophylaxis when patients have \( \geq 3 \) prolonged severe attacks a month that are incapacitating or unresponsive to symptomatic therapy or are likely to result in complications
- Lowest effective dose of propranolol (10-20 mg twice daily) is the drug of choice
  - If beta-blockers are used in the third trimester, treatment should be stopped two to three days before delivery
- Low-dose amitriptyline (10-25 mg daily) is an option

Sodium valproate, topiramate and methysergide are contraindicated during pregnancy
Pediatric Migraine

- Migraines are common in children
- Increase in frequency with increasing age
- Approximately 6% of adolescents experience migraine
- Mean age at onset: girls = 10.9 years; boys = 7.2 years
- Diagnosis is challenging because symptoms can vary significantly throughout childhood
- Not all adolescents will experience headaches throughout their lives
  - Up to 70% will experience some continuation of persistent or episodic migraines

Key Features for Diagnosis of Pediatric Migraine

- Duration tends to be shorter than in adults
- May be as short as 1 hour but can last 72 hours
- Often bifrontal or bitemporal rather than unilateral pain
- Children often have difficulty describing throbbing pain or levels of severity
- Using a face or numerical pain scale can be helpful
- Children often have difficulty describing symptoms
  - Symptoms often have to be inferred from the child’s behavior
- Consider associated symptoms (difficulty thinking, fatigue, lightheadedness)

Red Flags in the Diagnosis of Pediatric Migraine

- Increasing frequency and/or severity over several weeks (<4 months) in a child <12 years of age
  - Even more important in children <7 years of age
- A change of frequency and severity of headache pattern in young children
- Fever is not a component associated with migraine at any stage – especially in children
- Headaches accompanied by seizures
- Altered sensorium may occur in certain forms of migraine but it is not the norm
  - Needs attention to determine appropriate assessment and intervention

Pharmacotherapies for Pediatric and Adolescent Migraine

- Acute therapies should be used as soon as it is clear the headache is migraine
  - Ibuprofen and sumatriptan nasal spray are effective
  - Acetaminophen is probably effective
- Almotriptan is the only triptan currently approved by the FDA for treatment of migraine in patients ≥12 years of age
- Analgesics or acute medications should not be used >2 times per week unless patient is under medical supervision
- Supplementation with magnesium, riboflavin, and coenzyme Q10 may be helpful
- No medication currently approved by FDA for migraine prophylaxis in children
  - Some studies have shown topiramate to be effective

Pharmacological Preventative Treatment of Migraine
EFNS Guidelines for Initiating Prophylactic Therapy for Migraine

Consider and discuss prophylactic drug when:

• Quality of life, business duties, or school attendance are severely impaired
• Patient experiences ≥2 attacks per month
• Migraine attacks do not respond to acute drug treatment
• Frequent, very long, or uncomfortable auras occur

EFNS guidelines exclude the regular use (≥2 days/week) of medication, which is a frequent indication for prophylaxis, regardless of quality of life level

Migraine prophylaxis is regarded as successful if the frequency of migraine attacks per month is decreased by ≥50% within 3 months
Prophylactic Therapies in Migraine

- Antiepileptics
- Antidepressants
- Antihypertensives
- Vitamins/minerals/herbs
- OnabotulinumtoxinA
- Triptans (only in menstrual migraine- limit to 3-4 days)
- Antihistamines
- NSAIDs (only in menstrual migraine- limit to 3-4 days)

NSAID = non-steroidal anti-inflammatory drug
# Prophylaxis Treatments for Migraine

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blockers</td>
<td>• Most widely used drugs for migraine prophylaxis</td>
</tr>
<tr>
<td></td>
<td>• 60 to 80% effective in decreasing migraine frequency by &gt;50%</td>
</tr>
<tr>
<td></td>
<td>• Similar efficacy to topiramate</td>
</tr>
<tr>
<td></td>
<td>• Good tolerability</td>
</tr>
<tr>
<td></td>
<td>• Excellent choice for patients with hypertension, CAD</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>• TCAs most studied</td>
</tr>
<tr>
<td></td>
<td>• Amitriptyline decreases number and intensity of migraines by 50-70%</td>
</tr>
<tr>
<td>Topiramate</td>
<td>• Rapid onset of action (within first month)</td>
</tr>
<tr>
<td></td>
<td>• Showed to decrease mean monthly migraine periods</td>
</tr>
<tr>
<td></td>
<td>• Good tolerability in most patients</td>
</tr>
<tr>
<td>Valproate, divalproex</td>
<td>• First-line agents</td>
</tr>
<tr>
<td></td>
<td>• Divalproex is FDA approved</td>
</tr>
<tr>
<td></td>
<td>• Several delivery modes</td>
</tr>
<tr>
<td></td>
<td>• IV formulation of divalproex permit rapid achievement of therapeutic levels</td>
</tr>
<tr>
<td>OnabotulinumtoxinA</td>
<td>• FDA approved therapy for migraine</td>
</tr>
<tr>
<td></td>
<td>• Significantly reduces headache days/month vs. placebo</td>
</tr>
<tr>
<td></td>
<td>• Few associated adverse events</td>
</tr>
</tbody>
</table>

CAD = coronary artery disease; IV = intravenous; TCA = tricyclic antidepressant

Discussion Question

**What pharmacological approaches to managing MIGRAINE do you incorporate into your practice?**
Guidelines for the Pharmacological Management of Migraine

• AAN/AHS Guidelines
• CHS Guidelines for Acute Migraine Therapy
• CHS Guidelines – Prophylactic Drug Treatment Strategies
  • CHS Guidelines – Migraine Prophylaxis
• Latin American Consensus Guidelines for Chronic Migraine
  • EFNS Guideline on the Acute Treatment of Migraine
• EFNS Guideline on the Prophylactic Treatment of Migraine

Continue to Key Messages
## AAN/AHS Guidelines for Episodic Migraine Prevention in Adults

<table>
<thead>
<tr>
<th>Level A Medications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiepileptic drugs (divalproex sodium, sodium valproate, topiramate)</td>
<td></td>
</tr>
<tr>
<td>Beta-blockers (metoprolol, propranolol, timolol)</td>
<td></td>
</tr>
<tr>
<td>Triptans (Frovatriptan)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level B Medications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants (amitriptyline, venlafaxine)</td>
<td></td>
</tr>
<tr>
<td>Beta-blockers (atenolol, nadolol)</td>
<td></td>
</tr>
<tr>
<td>Triptans (naratriptan, zolmitriptan)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Third-line (Level C)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors (lisinopril)</td>
<td></td>
</tr>
<tr>
<td>Angiotensin receptor blockers (candesartan)</td>
<td></td>
</tr>
<tr>
<td>Alpha agonists (clonidine, guanfacine)</td>
<td></td>
</tr>
<tr>
<td>Antiepileptic drugs (carbamazepine)</td>
<td></td>
</tr>
<tr>
<td>Beta-blockers (nebivolol, pindolol)</td>
<td></td>
</tr>
<tr>
<td>Antihistamines (cyproheptadine)</td>
<td></td>
</tr>
</tbody>
</table>

---

AAN = American Academy of Neurology; ACE = angiotensin-converting-enzyme; AHS = American Headache Society; MRM = menstrually-related migraine; SSNRI = selective serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant

*Classification based on original guideline and new evidence not found for this report

*For short-term prophylaxis of menstrually-related migraine

**CHS Guidelines for Acute Migraine Therapy**

### Acute Migraine Treatment Strategies and Medication Summary: General Strategies

<table>
<thead>
<tr>
<th>Increasing migraine severity – Refractoriness to therapy</th>
<th>Clinical Phenotype</th>
<th>Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild-moderate attack strategies</td>
<td>a. Acetaminophen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. NSAID</td>
</tr>
<tr>
<td></td>
<td>Moderate-severe attack/NSAID failure strategies</td>
<td>a. NSAID with triptan rescue</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Triptan</td>
</tr>
<tr>
<td></td>
<td>Refractory migraine strategies</td>
<td>a. Triptan-NSAID combination</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Triptan-NSAID combination with rescue</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c. Dihydroergotamine</td>
</tr>
</tbody>
</table>

CHS = Canadian Headache Society; NSAID = non-steroidal anti-inflammatory drug

[Access full CHS guidelines](#)

[Return to guidelines list](#)
## CHS Guidelines for Migraine Prophylaxis

<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>First time strategy</td>
<td>a. Beta-blocker (propranolol, nadolol, metoprolol)</td>
</tr>
<tr>
<td></td>
<td>b. Tricyclic antidepressant</td>
</tr>
<tr>
<td>Low side effects</td>
<td>a. Candesartan, lisinopril</td>
</tr>
<tr>
<td></td>
<td>b. Herbal/vitamin/mineral (e.g., butterbur, riboflavin, magnesium)</td>
</tr>
<tr>
<td>Increased body mass</td>
<td>Topiramate</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Propranolol, nadolol, metoprolol, candesartan, lisinopril</td>
</tr>
<tr>
<td>Depression/anxiety</td>
<td>Amitriptyline, venlafaxine</td>
</tr>
<tr>
<td>Additional monotherapy</td>
<td>Topiramate, divalproex, gabapentin, pizotifen, flunarizine, verapamil</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Drug avoidance if possible</td>
</tr>
<tr>
<td></td>
<td>When necessary, magnesium, propranolol, metoprolol, amitriptyline</td>
</tr>
<tr>
<td>Lactation</td>
<td>Drug avoidance if possible</td>
</tr>
<tr>
<td></td>
<td>When necessary, magnesium, propranolol, metoprolol, amitriptyline, valproate</td>
</tr>
</tbody>
</table>

CHS = Canadian Headache Society
**CHS Guidelines for Migraine Prophylaxis**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiepileptics</strong></td>
<td>Divalproex sodium, valproic acid, sodium valproate, topiramate, gabapentin</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td>Amitriptyline, venlafaxine extended release</td>
</tr>
<tr>
<td><strong>Beta-blockers</strong></td>
<td>Propranolol, nadolol, metoprolol</td>
</tr>
<tr>
<td><strong>Calcium channel blockers</strong></td>
<td>Flunarizine, verapamil (not recommended for routine use)</td>
</tr>
<tr>
<td><strong>ACEIs/ARBs</strong></td>
<td>Candesartan, lisinopril</td>
</tr>
<tr>
<td><strong>Serotonin agonists</strong></td>
<td>Pizotifen</td>
</tr>
<tr>
<td><strong>Vitamins/minerals/herbals</strong></td>
<td>Riboflavin, coenzyme Q10, magnesium citrate, butterbur (petasites)</td>
</tr>
</tbody>
</table>

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; AV = atrioventricular; BID = twice daily; CHF = congestive heart failure; CHS = Canadian Headache Society; CNS = central nervous system; CV = cardiovascular; GI = gastrointestinal; LA = long acting; MI = myocardial infarction; SNRI = serotonin-norepinephrine reuptake inhibitor; SR = sustained release; TCA = tricyclic antidepressant; TID = three times daily

# Latin American Consensus on Guidelines for Chronic Migraine Treatment

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topiramate</td>
<td>Use in prophylaxis is based on class I studies with level A evidence</td>
</tr>
<tr>
<td>Sodium valproate, divalproate</td>
<td>Recommended in prophylaxis of episodic migraine (class I studies with level A evidence)</td>
</tr>
<tr>
<td>Amitriptyline, Gabapentin, Pregabalin, Tizanidine</td>
<td>Studied for chronic daily headache by revealing efficacy (evidence levels I to III); not specifically researched for migraine</td>
</tr>
<tr>
<td>Type A botulinum toxin</td>
<td>For prophylaxis of chronic migraine in patients aged 18 to 65 years</td>
</tr>
<tr>
<td>Non-pharmacologic measures/complementary therapies</td>
<td>Use is limited due lack of studies. Exception = acupuncture (promising results)</td>
</tr>
</tbody>
</table>

Medicines already proven as preventive for episodic migraine can be used alone or in combination, even without any evidence of their efficacy for chronic migraine

Access full Latin American guidelines

Return to guidelines list
# EFNS Guideline on the Treatment of Migraine – Acute Therapies

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>• Drugs of first choice for mild or moderate attacks</td>
</tr>
<tr>
<td></td>
<td>• Restrict intake of simple analgesics to 15 days/month</td>
</tr>
<tr>
<td></td>
<td>• Restrict intake of combined analgesics to 10 days/month</td>
</tr>
<tr>
<td>Antiemetics</td>
<td>• Recommended for nausea and potential vomiting</td>
</tr>
<tr>
<td></td>
<td>• Assumed to improve resorption of analgesics</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
<td>• Restrict to patients with very long migraine attacks or with regular occurrence</td>
</tr>
<tr>
<td></td>
<td>• Limit use to 10 days/month</td>
</tr>
<tr>
<td>Triptans</td>
<td>• Efficacy proven in large placebo-controlled trials and meta-analyses</td>
</tr>
<tr>
<td></td>
<td>• Use restricted to maximum 9 days/month by IHS criteria</td>
</tr>
<tr>
<td></td>
<td>• Should not be taken during the aura</td>
</tr>
<tr>
<td>Opioids</td>
<td>• Should not be used in the acute treatment of migraine</td>
</tr>
<tr>
<td>Tranquillizers</td>
<td></td>
</tr>
</tbody>
</table>

EFNS = European Federation of Neurological Societies; IHS = International Headache Society

# EFNS Guideline on the Treatment of Migraine – Prophylactic Therapies

<table>
<thead>
<tr>
<th>First-line (Level A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blockers (metoprolol, propranolol)</td>
</tr>
<tr>
<td>Calcium channel blockers (flunarizine)</td>
</tr>
<tr>
<td>Antiepileptic drugs (valproic acid, topiramate)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line (Level B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
</tr>
<tr>
<td>Venlafaxine</td>
</tr>
<tr>
<td>Naproxen</td>
</tr>
<tr>
<td>Butterbur (petasites)</td>
</tr>
<tr>
<td>Bisoprolol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Third-line (Level C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylsalicylic acid (ASA)</td>
</tr>
<tr>
<td>Gabapentin</td>
</tr>
<tr>
<td>Magnesium</td>
</tr>
<tr>
<td>Tanacetum parthenium</td>
</tr>
<tr>
<td>Riboflavin</td>
</tr>
<tr>
<td>Coenzyme Q10</td>
</tr>
<tr>
<td>Candesartan</td>
</tr>
<tr>
<td>Lisinopril</td>
</tr>
<tr>
<td>Methysergide</td>
</tr>
</tbody>
</table>

EFNS = European Federation of Neurological Societies; IHS = International Headache Society
Key Messages

• Headache is extremely common
  – Migraine and tension-type headache are the most common presentation in primary care

• Clinicians should maintain high degree of awareness for “red flags” indicating potential serious disorders
  – When possible, clinicians should treat the underlying cause of headache

• The mechanisms of pain in migraine include meningeal vasodilation, neurogenic inflammation, and peripheral and central neuronal sensitization and pain processing
  – These may be modified using migraine treatments

• Timely and appropriate treatment may help prevent episodic migraine from becoming chronic migraine and medication overuse headache
References

Allergan. BOTOX® (onabotulinumtoxinA) Prescribing Information, February 2014.


References


References


References


Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416.


References


